clinical trial · NCT03970616
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
AVEO Pharmaceuticals, Inc.·phase2·terminated·n = 27
Hepatocellular CarcinomaTivozanibDurvalumab
brief summary
This study will evaluate the safety, tolerability, DLTs, MTD, and preliminary anti tumor activity of tivozanib in combination with durvalumab in subjects with advanced HCC.
started
Sep 30, 2019
primary completion
Apr 4, 2023
completion
Apr 4, 2023
last updated
Jul 12, 2023
official title
A Phase 1b/2, Open-Label, Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol